Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 14/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 0.70 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raloxifene Core SCHEMBL29941293 | 1.00 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL13071222 | 0.89 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL19171602 | 0.89 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL3139631 | 0.89 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL204092 | 0.89 | ESR1 (0.80) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL7643423 | 0.89 | ESR1 (1.00) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL27364075 | 0.86 | ESR1 (0.76) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL7774208 | 0.85 | ESR2 (0.74) | ESR1ESR2APPHSD17B1HSD17B2 | |
| SCHEMBL498648 | 0.85 | ESR2 (0.73) | ESR1ESR2APP | |
| SCHEMBL3148543 | 0.85 | ESR1 (0.73) | ESR1ESR2APPHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2018-08-02 | — | — | US | claimed |
| US-20170100371-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | UNIV ILLINOIS (US) | 2017-04-13 | — | — | US | claimed |
| US-20150291552-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-10-15 | — | — | US | claimed |
| EP-2911660-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | The Board of Trustees of the University of Illinois (US) | 2015-09-02 | — | — | EP | claimed |
| WO-2014066692-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-05-01 | — | — | WO | claimed |
| WO-2005003116-A9 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-09-25 | — | — | WO | claimed |
| EP-1641773-B1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE SPA (IT) | 2008-07-23 | — | — | EP | claimed |
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | ERREGIERRE S.P.A (IT) | 2007-05-03 | — | — | US | claimed |
| EP-1641773-A1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE S.p.A. (IT) | 2006-04-05 | — | — | EP | claimed |
| WO-2005003116-A1 | PROCESS FOR PREPARING RALOXIFENE HYDROCHLORIDE | ERREGIERRE S.P.A. (IT) | 2005-01-13 | — | — | WO | claimed |
| US-6395769-B1 | ACTIVATION ESTROGEN; THERAPY FOR OSTEOPOROSIS, ANTILIPEMIC AGENTS | ELI LILLY AND COMPANY | 2002-05-28 | — | — | US | claimed |
| US-6096781-A | 2-PHENYL-1-BENZOTHIOPHENE DERIVATIVES ARE USEFUL FOR TREATMENT OF OSTEOPOROSIS AND HYPERLIPEMIA | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | claimed |
| EP-0920862-A1 | 2-Arylbenzo b thiophenes useful for the treatment of estrogen deprivation syndrome | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | claimed |
| WO-1992021669-A1 | 2-PHENYLBENZO[B]FURANS AND THIOPHENES, METHODS OF PREPARING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-10 | — | — | WO | claimed |
| EP-0516257-A1 | Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-02 | — | — | EP | claimed |
| EP-4686757-A1 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | e-therapeutics PLC (GB) | 2026-02-04 | — | — | EP | disclosed |
| CN-119264362-A | Water-based polyurethane resin with side chain containing heterocyclic group and preparation method thereof | 惠州市亨迪树脂制品有限公司 | 2025-01-07 | — | — | CN | disclosed |
| EP-0062503-A1 | Benzothiophene compounds and process for preparing them | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
| EP-0062504-A1 | Process for preparing 3-(4-aminoethoxybenzoyl)benzo(b)thiophenes | ELI LILLY AND COMPANY (US) | 1982-10-13 | — | — | EP | disclosed |
| US-4133814-A | ANTITUMOR AGENTS | ELI LILLY AND COMPANY (US) | 1979-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100147-A1 | Process for preparing raloxifene hydrochloride | KAT2A, ADH1A, KAT2B | ESR1 78/4885ESR2 69/4885APP 4316/4885 |
| US-20170100371-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | ESR1 11/4885ESR2 5/4885APP 4504/4885 |
| US-20180214414-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | ESR1 11/4885ESR2 5/4885APP 4504/4885 |
| US-20150291552-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, SHBG, ESRRB | ESR1 11/4885ESR2 5/4885APP 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.